Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Makoto Okawaki

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 16, 2015
[Current Cancer Immunotherapy Using Activated Lymphocytes - Do Lymphocytes Actually Recognize Cancer Cells ?]Yoshiyuki Yamaguchi, Yousuke Katata, Makoto Okawaki, et al.
Anticancer Research|November 11, 2006
Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432Katsuji Hironaka, Yoshiyuki Yamaguchi, Riki Okita, et al.
Anticancer Research|January 30, 2022
Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients With Incurable Pancreatic CancerYoshiyuki Yamaguchi, Yousuke Katata, Makoto Okawaki, et al.
Anticancer Research|April 30, 2016
A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic CancerYoshiyuki Yamaguchi, Yousuke Katata, Makoto Okawaki, et al.
Hiroshima Journal of Medical Sciences|June 27, 2008
Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusionMakoto Okawaki, Yoshiyuki Yamaguchi, Riki Okita, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 26, 2018
[Introduction]Yoshiyuki Yamaguchi, Yosuke Katata, Makoto Okawaki, et al.
Molecular and Clinical Oncology|December 9, 2021
Erratum: Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational studyYoshiyuki Yamaguchi, Yousuke Katata, Fuminori Sano, et al.
Molecular and Clinical Oncology|September 9, 2020
Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational studyYoshiyuki Yamaguchi, Yousuke Katata, Fuminori Sano, et al.
Anticancer Research|May 5, 2005
HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumabYoshiyuki Yamaguchi, Katsuji Hironaka, Makoto Okawaki, et al.
Cancer Diagnosis & Prognosis|July 5, 2023
Spinal Instability as a Prognostic Factor in Patients With Spinal Metastasis of Castration-resistant Prostate CancerYoshiyuki Miyaji, Kazuo Nakanishi, Akira Yamamoto, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 16, 2015
[Current Cancer Immunotherapy Using Activated Lymphocytes - Do Lymphocytes Actually Recognize Cancer Cells ?]Yoshiyuki Yamaguchi, Yousuke Katata, Makoto Okawaki, et al.
Anticancer Research|November 11, 2006
Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432Katsuji Hironaka, Yoshiyuki Yamaguchi, Riki Okita, et al.
Anticancer Research|January 30, 2022
Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients With Incurable Pancreatic CancerYoshiyuki Yamaguchi, Yousuke Katata, Makoto Okawaki, et al.
Anticancer Research|April 30, 2016
A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic CancerYoshiyuki Yamaguchi, Yousuke Katata, Makoto Okawaki, et al.
Hiroshima Journal of Medical Sciences|June 27, 2008
Dose-finding study of anti-CD25 antibody for targeting regulatory T cells in locoregional immunotherapy of malignant effusionMakoto Okawaki, Yoshiyuki Yamaguchi, Riki Okita, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 26, 2018
[Introduction]Yoshiyuki Yamaguchi, Yosuke Katata, Makoto Okawaki, et al.
Molecular and Clinical Oncology|December 9, 2021
Erratum: Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational studyYoshiyuki Yamaguchi, Yousuke Katata, Fuminori Sano, et al.
Molecular and Clinical Oncology|September 9, 2020
Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational studyYoshiyuki Yamaguchi, Yousuke Katata, Fuminori Sano, et al.
Anticancer Research|May 5, 2005
HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumabYoshiyuki Yamaguchi, Katsuji Hironaka, Makoto Okawaki, et al.
Cancer Diagnosis & Prognosis|July 5, 2023
Spinal Instability as a Prognostic Factor in Patients With Spinal Metastasis of Castration-resistant Prostate CancerYoshiyuki Miyaji, Kazuo Nakanishi, Akira Yamamoto, et al.
Pageof 3